Article
Medicine, Research & Experimental
Jani Huuhtanen, Mette Ilander, Bhagwan Yadav, Olli M. J. Dufva, Hanna Lahteenmaki, Tiina Kasanen, Jay Klievink, Ulla Olsson-Stromberg, Jesper Stentoft, Johan Richter, Perttu Koskenvesa, Martin Hoglund, Stina Soderlund, Arta Dreimane, Kimmo Porkka, Tobias Gedde-Dahl, Bjorn T. Gjertsen, Leif Stenke, Kristina Myhr-Eriksson, Berit Markevarn, Anna Lubking, Andreja Dimitrijevic, Lene Udby, Ole Weis Bjerrum, Henrik Hjorth-Hansen, Satu Mustjoki
Summary: In patients with chronic myeloid leukemia, combination therapy with dasatinib and IFN-alpha can improve deep molecular remission and restore immune function.
JOURNAL OF CLINICAL INVESTIGATION
(2022)
Article
Pharmacology & Pharmacy
Hyacinthe Johnson-Ansah, Benjamin Maneglier, Francoise Huguet, Laurence Legros, Martine Escoffre-Barbe, Martine Gardembas, Pascale Cony-Makhoul, Valerie Coiteux, Laurent Sutton, Wajed Abarah, Camille Pouaty, Jean-Michel Pignon, Bachra Choufi, Sorin Visanica, Benedicte Deau, Laure Morisset, Emilie Cayssials, Mathieu Molimard, Stephane Bouchet, Francois-Xavier Mahon, Franck Nicolini, Philippe Aegerter, Jean-Michel Cayuela, Marc Delord, Heriberto Bruzzoni-Giovanelli, Philippe Rousselot
Summary: This study evaluated the value of therapeutic drug monitoring (TDM) in imatinib treatment for patients with chronic myelogenous leukemia. The results showed that TDM strategy significantly increased the plasma concentration of imatinib and improved the treatment outcome for patients.
Article
Oncology
Timothy P. Hughes, Nelma Cristina D. Clementino, Mikhail Fominykh, Jeffrey H. Lipton, Anna G. Turkina, Elena Beatriz Moiraghi, Franck E. Nicolini, Naoto Takahashi, Tomasz Sacha, Dong-Wook Kim, Rafik Fellague-Chebra, Ranjan Tiwari, Catherine Bouard, Francois-Xavier Mahon
Summary: The ENESTop study demonstrated the durability and safety of treatment-free remission (TFR) in chronic myeloid leukemia patients who achieved sustained deep molecular response with nilotinib. Overall adverse event rates decreased over 5 years of TFR, but there was a cumulative increase in cardiovascular events with longer nilotinib exposure when reinitiating treatment.
Article
Oncology
Axel Karow, Gudrun Goehring, Stephanie Sembill, Friederike Lutterloh, Fina Neuhaus, Sara Callies, Elke Schirmer, Zofia Wotschofsky, Oisin Roche-Lancaster, Meinolf Suttorp, Manuela Krumbholz, Markus Metzler
Summary: This study analyzed non-Philadelphia chromosome aberrations (nPhAs) in a cohort of 161 pediatric chronic myeloid leukemia (CML) patients. The study found a distinct distribution of nPhAs in this pediatric cohort, which may impact treatment response but not survival. These findings highlight the unique biology of pediatric CML and emphasize the need for international collaboration to acquire more data on the disease in this age group.
Article
Medicine, General & Internal
Natalia Estrada, Lurdes Zamora, Francisca Ferrer-Marin, Laura Palomo, Olga Garcia, Patricia Velez, Iris De la Fuente, Miguel Sagues, Marta Cabezon, Montserrat Cortes, Rolando Omar Vallansot, Maria Alicia Senin-Magan, Concepcion Boque, Blanca Xicoy
Summary: This study aimed to understand the contribution of germline single-nucleotide variants to the response of chronic myeloid leukemia patients to imatinib treatment. Through analyzing different patient cohorts, the study identified 7 gSNVs and one gene haplotype significantly associated with the response to imatinib therapy.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Multidisciplinary Sciences
Christian Volz, Thomas Zerjatke, Andrea Gottschalk, Sabine Semper, Meinolf Suttorp, Ingmar Glauche, Manuela Krumbholz, Markus Metzler
Summary: This study analyzed the molecular response kinetics to TKI therapy in 129 pediatric CML patients and investigated the role of response assessment based on continuous references in individual therapy adjustment. The high-resolution response target curve of the optimal responder group proved to be a valuable tool for continuous therapy monitoring of individual pediatric CML patients.
SCIENTIFIC REPORTS
(2023)
Article
Hematology
Aram Bidikian, Elias Jabbour, Ghayas C. C. Issa, Nicholas J. J. Short, Koji Sasaki, Hagop Kantarjian
Summary: Achieving major molecular response (MMR) with BCR::ABL1 tyrosine kinase inhibitors (TKIs) is important in the treatment of chronic myeloid leukemia (CML). However, patients who achieve a major cytogenetic response (MCyR) within the first 2 years of TKI therapy can still have good long-term outcomes, even without achieving MMR. The value of MMR is less pronounced among older CML patients, who often face mortality due to comorbidities unrelated to CML.
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Article
Oncology
Ryan Yen, Sarah Grasedieck, Andrew Wu, Hanyang Lin, Jiechuang Su, Katharina Rothe, Helen Nakamoto, Donna L. Forrest, Connie J. Eaves, Xiaoyan Jiang
Summary: This study analyzed differentially expressed miRNAs in CML patients, showing that the combination of miR-145 and miR-708 effectively predicts response to NL in treatment-naive patients, while miR-150 and miR-185 are significant classifiers at 1 month and 3 months post-NL therapy.
Article
Biochemistry & Molecular Biology
Yi-Hue Kuo, Shih-Hsiang Wei, Jie-Hau Jiang, Yueh-Shih Chang, Mei-Yin Liu, Shu-Ling Fu, Chi-Ying F. Huang, Wey-Jinq Lin
Summary: This study demonstrates that the deficiency of p38 alpha can enhance the therapeutic efficacy of TKIs on CML cells, while p38 beta deficiency has opposite effects. Specific inhibitors targeting p38 alpha also show potential in enhancing the therapeutic efficacy of TKIs, providing feasibility for future clinical applications.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Lioba Schoenfeld, Jenny Rinke, Anna Hinze, Saskia N. Nagel, Vivien Schaefer, Thomas Schenk, Christian Fabisch, Tim H. Bruemmendorf, Andreas Burchert, Philipp le Coutre, Stefan W. Krause, Susanne Saussele, Fatemeh Safizadeh, Markus Pfirrmann, Andreas Hochhaus, Thomas Ernst
Summary: Gene mutations independent of BCR::ABL1, especially in epigenetic modifier genes, are common in newly diagnosed patients with chronic myeloid leukemia in chronic phase. Specifically, ASXL1 mutations have been found to be the most commonly affected. These mutations are associated with less favorable molecular response to nilotinib treatment, and patients carrying ASXL1 mutations are typically younger and more frequently classified as high risk, suggesting a central role of clonal evolution associated with ASXL1 mutations in CML pathogenesis.
Review
Biochemistry & Molecular Biology
Alexander Rudich, Ramiro Garzon, Adrienne Dorrance
Summary: Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm initiated by the presence of the fusion gene BCR::ABL1, and therapy resistance remains a persistent problem in the pursuit of a cure, with non-coding RNAs (ncRNAs) playing an important role in CML therapy resistance.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Biochemistry & Molecular Biology
Xiuyan Zhang, Yu Wang, Jinchang Lu, Lun Xiao, Hui Chen, Quanxue Li, Yuan-Yuan Li, Peng Xu, Changgeng Ruan, Haixia Zhou, Yun Zhao
Summary: This study identified a novel ZFX/WNT3 axis that modulates the growth and drug response of CML stem/progenitor cells.
CELLULAR & MOLECULAR BIOLOGY LETTERS
(2023)
Article
Hematology
Ahlam Nasser, Ally Hussein, Clara Chamba, Mbonea Yonazi, Rosemary Mushi, Anna Schuh, Lucio Luzzatto
Summary: Imatinib is the main treatment for chronic myeloid leukemia in Tanzania, but the majority of patients do not achieve deep molecular response, likely due to late diagnosis, cytopenias requiring drug interruptions, and poor treatment adherence.
Article
Biochemistry & Molecular Biology
Sylwester Glowacki, Ewelina Synowiec, Marzena Szwed, Monika Toma, Tomasz Skorski, Tomasz Sliwinski
Summary: Chronic myeloid leukemia (CML) is caused by the BCR-ABL1 protein, inducing oxidative stress and leading to resistance to imatinib (IM). Research shows increased ROS accumulation in BCR-ABL1 positive cells, heightened DNA damage in IM-sensitive cells, and alterations in antioxidant enzyme activity and mitochondrial potential in IM-resistant cells.
Article
Hematology
Hagop M. Kantarjian, Elias Jabbour, Michael Deininger, Elisabetta Abruzzese, Jane Apperley, Jorge Cortes, Charles Chuah, Daniel J. DeAngelo, John DiPersio, Andreas Hochhaus, Jeffrey Lipton, Franck E. Nicolini, Javier Pinilla-Ibarz, Delphine Rea, Gianantonio Rosti, Philippe Rousselot, Neil P. Shah, Moshe Talpaz, Shouryadeep Srivastava, Xiaowei Ren, Michael Mauro
Summary: Ponatinib has demonstrated deep and durable responses in patients with chronic-phase chronic myeloid leukemia, especially in those resistant to second-generation TKI treatment, and has shown good safety and survival outcomes.
AMERICAN JOURNAL OF HEMATOLOGY
(2022)